Trial Profile
Phase 2 study of AB-SA01 in Staphylococcal infections patients with Chronic Rhinosinusitis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2017
Price :
$35
*
At a glance
- Drugs AP SA01 (Primary)
- Indications Staphylococcal infections
- Focus Therapeutic Use
- 17 Apr 2017 According to an AmpliPhi Biosciences media release, the US FDA has provided positive feedback on the company's previously submitted detailed development proposal to commence this trial.
- 04 Jan 2017 According to an AmpliPhi Biosciences Corporation media release, company intends to initiate this study in the second half of 2017.
- 09 Nov 2016 New trial record